;PMID: 8669886
;source_file_2839.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:52..128] = [t:52..128]
;2)section:[e:132..217] = [t:132..217]
;3)section:[e:221..276] = [t:221..276]
;4)sentence:[e:280..519] = [t:280..519]
;5)sentence:[e:520..638] = [t:520..638]
;6)sentence:[e:639..900] = [t:639..900]
;7)sentence:[e:901..1048] = [t:901..1048]
;8)sentence:[e:1049..1268] = [t:1049..1268]
;9)section:[e:1272..1316] = [t:1272..1316]

;section 0 Span:0..46
;Anticancer Res.  1995 Nov-Dec;15(6B):2899-905.
(SEC
  (FRAG (NNP:[0..10] Anticancer) (NNP:[11..14] Res) (.:[14..15] .)
        (CD:[17..21] 1995) (NNP:[22..29] Nov-Dec) (::[29..30] ;)
        (CD:[30..32] 15) (-LRB-:[32..33] -LRB-) (NN:[33..35] 6B)
        (-RRB-:[35..36] -RRB-) (::[36..37] :) (CD:[37..45] 2899-905)
        (.:[45..46] .)))

;sentence 1 Span:52..128
;N-myc protein expression in human breast carcinoma: prognostic implications.
;[52..57]:gene-protein:"N-myc"
;[86..102]:malignancy-type:"breast carcinoma"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[52..57] N-myc) (NN:[58..65] protein) (NN:[66..76] expression))
      (PP (IN:[77..79] in)
        (NP (JJ:[80..85] human)
           (NN:[86..92] breast) (NN:[93..102] carcinoma))))
    (::[102..103] :)
    (NP (JJ:[104..114] prognostic) (NNS:[115..127] implications))
    (.:[127..128] .)))

;section 2 Span:132..217
;Mizukami Y, Nonomura A, Takizawa T, Noguchi M, Michigishi T, Nakamura S, 
;Ishizaki T.
(SEC
  (FRAG (NNP:[132..140] Mizukami) (NNP:[141..142] Y) (,:[142..143] ,)
        (NNP:[144..152] Nonomura) (NNP:[153..154] A) (,:[154..155] ,)
        (NNP:[156..164] Takizawa) (NNP:[165..166] T) (,:[166..167] ,)
        (NNP:[168..175] Noguchi) (NNP:[176..177] M) (,:[177..178] ,)
        (NNP:[179..189] Michigishi) (NNP:[190..191] T) (,:[191..192] ,)
        (NNP:[193..201] Nakamura) (NNP:[202..203] S) (,:[203..204] ,)
        (NNP:[206..214] Ishizaki) (NNP:[215..216] T) (VBD:[216..217] .)))

;section 3 Span:221..276
;Pathology Section, Kanazawa University Hospital, Japan.
(SEC
  (FRAG (NNP:[221..230] Pathology) (NNP:[231..238] Section) (,:[238..239] ,)
        (NNP:[240..248] Kanazawa) (NNP:[249..259] University)
        (NNP:[260..268] Hospital) (,:[268..269] ,) (NNP:[270..275] Japan)
        (.:[275..276] .)))

;sentence 4 Span:280..519
;The overexpression of N-myc gene and its protein products has been thought to
;be  limited to cases of neuroblastoma, retinoblastoma and small cell lung
;carcinoma,  but there is increasing evidence of its wider distribution in
;human tumors.
;[302..307]:gene-rna:"N-myc"
;[317..337]:gene-protein:"its protein products"
;[382..395]:malignancy-type:"neuroblastoma"
;[397..411]:malignancy-type:"retinoblastoma"
;[416..441]:malignancy-type:"small cell lung carcinoma"
(SENT
  (S
    (S
      (NP-SBJ-1
        (NP (DT:[280..283] The) (NN:[284..298] overexpression))
        (PP (IN:[299..301] of)
          (NP
            (NP (NN:[302..307] N-myc) (NN:[308..312] gene))
            (CC:[313..316] and)
            (NP (PRP$:[317..320] its) (NN:[321..328] protein)
                (NNS:[329..337] products)))))
      (VP (VBZ:[338..341] has)
        (VP (VBN:[342..346] been)
          (VP (VBN:[347..354] thought)
            (S
              (NP-SBJ-1 (-NONE-:[354..354] *))
              (VP (TO:[355..357] to)
                (VP (VB:[358..360] be)
                  (VP (VBN:[362..369] limited)
                    (NP-1 (-NONE-:[369..369] *))
                    (PP-CLR (TO:[370..372] to)
                      (NP
                        (NP (NNS:[373..378] cases))
                        (PP (IN:[379..381] of)
                          (NP
                            (NP (NN:[382..395] neuroblastoma))
                            (,:[395..396] ,)
                            (NP (NN:[397..411] retinoblastoma))
                            (CC:[412..415] and)
                            (NP
                              (NML (JJ:[416..421] small) (NN:[422..426] cell))
                              (NN:[427..431] lung) (NN:[432..441] carcinoma))))))))))))))
    (,:[441..442] ,) (CC:[444..447] but)
    (S
      (NP-SBJ (EX:[448..453] there))
      (VP (VBZ:[454..456] is)
        (NP-PRD
          (NP (VBG:[457..467] increasing) (NN:[468..476] evidence))
          (PP (IN:[477..479] of)
            (NP (PRP$:[480..483] its) (JJR:[484..489] wider)
                (NN:[490..502] distribution))))
        (PP (IN:[503..505] in)
          (NP (JJ:[506..511] human) (NNS:[512..518] tumors)))))
    (.:[518..519] .)))

;sentence 5 Span:520..638
;This  study showed that the protein of N-myc gene is associated in normal,
;benign and  malignant human breast tissues.
;[544..555]:gene-protein:"the protein"
;[559..564]:gene-rna:"N-myc"
(SENT
  (S
    (NP-SBJ (DT:[520..524] This) (NN:[526..531] study))
    (VP (VBD:[532..538] showed)
      (SBAR (IN:[539..543] that)
        (S
          (NP-SBJ-1
            (NP (DT:[544..547] the) (NN:[548..555] protein))
            (PP (IN:[556..558] of)
              (NP (NN:[559..564] N-myc) (NN:[565..569] gene))))
          (VP (VBZ:[570..572] is)
            (VP (VBN:[573..583] associated)
              (NP-1 (-NONE-:[583..583] *))
              (PP-LOC (IN:[584..586] in)
                (NP
                  (NP (JJ:[587..593] normal)
                    (NML-2 (-NONE-:[593..593] *P*)))
                  (,:[593..594] ,)
                  (NP (JJ:[595..601] benign)
                    (NML-2 (-NONE-:[601..601] *P*)))
                  (CC:[602..605] and)
                  (NP (JJ:[607..616] malignant)
                    (NML-2 (JJ:[617..622] human) (NN:[623..629] breast)
                           (NNS:[630..637] tissues))))))))))
    (.:[637..638] .)))

;sentence 6 Span:639..900
;We found that N-myc oncoprotein is overexpressed  in most breast carcinomas
;and that N-myc overexpression is significantly  correlated with clinical
;stage, and histological grading of the tumors, and,  more importantly with
;the clinical outcome of the patients.
;[653..658]:gene-protein:"N-myc"
;[697..714]:malignancy-type:"breast carcinomas"
;[724..729]:gene-protein:"N-myc"
(SENT
  (S
    (NP-SBJ (PRP:[639..641] We))
    (VP (VBD:[642..647] found)
      (SBAR
        (SBAR (IN:[648..652] that)
          (S
            (NP-SBJ-1 (NN:[653..658] N-myc) (NN:[659..670] oncoprotein))
            (VP (VBZ:[671..673] is)
              (VP (VBN:[674..687] overexpressed)
                (NP-1 (-NONE-:[687..687] *))
                (PP-LOC (IN:[689..691] in)
                  (NP (JJS:[692..696] most)
                     (NN:[697..703] breast) (NNS:[704..714] carcinomas)))))))
        (CC:[715..718] and)
        (SBAR (IN:[719..723] that)
          (S
            (NP-SBJ-2 (NN:[724..729] N-myc) (NN:[730..744] overexpression))
            (VP (VBZ:[745..747] is)
              (ADVP (RB:[748..761] significantly))
              (VP (VBN:[763..773] correlated)
                (NP-2 (-NONE-:[773..773] *))
                (PP-CLR
                  (PP (IN:[774..778] with)
                    (NP
                      (NP
                        (NP (JJ:[779..787] clinical) (NN:[788..793] stage))
                        (,:[793..794] ,) (CC:[795..798] and)
                        (NP (JJ:[799..811] histological) (NN:[812..819] grading)))
                      (PP (IN:[820..822] of)
                        (NP (DT:[823..826] the) (NNS:[827..833] tumors)))))
                  (,:[833..834] ,) (CC:[835..838] and) (,:[838..839] ,)
                  (PP
                    (ADVP (RBR:[841..845] more) (RB:[846..857] importantly))
                    (IN:[858..862] with)
                    (NP
                      (NP (DT:[863..866] the) (JJ:[867..875] clinical)
                          (NN:[876..883] outcome))
                      (PP (IN:[884..886] of)
                        (NP (DT:[887..890] the) (NNS:[891..899] patients))))))))))))
    (.:[899..900] .)))

;sentence 7 Span:901..1048
;Analysis of DNA,  mRNA and protein levels suggested that the high N-myc
;expression in breast  cancer occurs without concomitant gene amplification.
;[967..972]:gene-generic:"N-myc"
;[987..1001]:malignancy-type:"breast  cancer"
;[1034..1047]:variation-type:"amplification"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[901..909] Analysis))
      (PP (IN:[910..912] of)
        (NP
          (NP (NN:[913..916] DNA))
          (,:[916..917] ,)
          (NP (NN:[919..923] mRNA))
          (CC:[924..927] and)
          (NP (NN:[928..935] protein) (NNS:[936..942] levels)))))
    (VP (VBD:[943..952] suggested)
      (SBAR (IN:[953..957] that)
        (S
          (NP-SBJ
            (NP (DT:[958..961] the) (JJ:[962..966] high) (NN:[967..972] N-myc)
                (NN:[973..983] expression))
            (PP (IN:[984..986] in)
              (NP (NN:[987..993] breast) (NN:[995..1001] cancer))))
          (VP (VBZ:[1002..1008] occurs)
            (PP (IN:[1009..1016] without)
              (NP (JJ:[1017..1028] concomitant) (NN:[1029..1033] gene)
                  (NN:[1034..1047] amplification)))))))
    (.:[1047..1048] .)))

;sentence 8 Span:1049..1268
;The finding of a direct  inverse correlation between N-myc overexpression and
;the prognosis of patients  with breast carcinoma suggests that N-myc
;expression may be useful as a  prognostic factor in human breast cancer.
;[1102..1107]:gene-generic:"N-myc"
;[1159..1175]:malignancy-type:"breast carcinoma"
;[1190..1195]:gene-generic:"N-myc"
;[1254..1267]:malignancy-type:"breast cancer"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1049..1052] The) (NN:[1053..1060] finding))
      (PP (IN:[1061..1063] of)
        (NP
          (NP (DT:[1064..1065] a) (JJ:[1066..1072] direct)
              (JJ:[1074..1081] inverse) (NN:[1082..1093] correlation))
          (PP (IN:[1094..1101] between)
            (NP
              (NP (NN:[1102..1107] N-myc) (NN:[1108..1122] overexpression))
              (CC:[1123..1126] and)
              (NP
                (NP (DT:[1127..1130] the) (NN:[1131..1140] prognosis))
                (PP (IN:[1141..1143] of)
                  (NP
                    (NP (NNS:[1144..1152] patients))
                    (PP (IN:[1154..1158] with)
                      (NP (NN:[1159..1165] breast) (NN:[1166..1175] carcinoma)))))))))))
    (VP (VBZ:[1176..1184] suggests)
      (SBAR (IN:[1185..1189] that)
        (S
          (NP-SBJ (NN:[1190..1195] N-myc) (NN:[1196..1206] expression))
          (VP (MD:[1207..1210] may)
            (VP (VB:[1211..1213] be)
              (ADJP-PRD (JJ:[1214..1220] useful))
              (PP (IN:[1221..1223] as)
                (NP (DT:[1224..1225] a) (JJ:[1227..1237] prognostic)
                    (NN:[1238..1244] factor)))
              (PP (IN:[1245..1247] in)
                (NP (JJ:[1248..1253] human)
                   (NN:[1254..1260] breast) (NN:[1261..1267] cancer))))))))
    (.:[1267..1268] .)))

;section 9 Span:1272..1316
;PMID: 8669886 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1272..1276] PMID) (::[1276..1277] :) (CD:[1278..1285] 8669886)
        (NN:[1286..1287] -LSB-) (NNP:[1287..1293] PubMed) (::[1294..1295] -)
        (NN:[1296..1303] indexed) (IN:[1304..1307] for)
        (NNP:[1308..1315] MEDLINE) (-RRB-:[1315..1316] -RSB-)))
